Gynecology

Cervical Cancer:

HIRB #pend/ Merck #KEYNOTE-826: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Chemotherapy Plus Placebo for the First-Line Treatment of Persistent, Recurrent, or Metastatic Cervical Cancer (not yet submitted to IRB)